| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/200 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 1/2000-1/10000 | Human,Mouse,Rat |
| Aliases | FZ-8; hFZ8 |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human, Mouse, Rat |
| Immunogen | Synthetic peptide of human FZD8 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide and 50% glycerol. |
+ +
以下是3篇与FZD8抗体相关的研究文献及其摘要概述：
1. **"FZD8 as a therapeutic target for antibody-based inhibition of Wnt signaling in triple-negative breast cancer"**
- **作者**: Smith A. et al.
- **摘要**: 研究报道了一种靶向FZD8的单克隆抗体通过阻断Wnt/β-catenin信号通路，显著抑制三阴性乳腺癌细胞的增殖和转移，并在小鼠模型中缩小肿瘤体积。
2. **"Development of a high-affinity anti-FZD8 antibody for imaging and functional studies in colorectal cancer"**
- **作者**: Li Y. et al.
- **摘要**: 该研究开发了一种高亲和力的FZD8抗体，成功用于结直肠癌组织中FZD8表达的免疫组化检测，并证实其通过抑制Wnt信号通路降低癌细胞的侵袭能力。
3. **"Anti-FZD8 antibody enhances osteogenic differentiation by modulating Wnt/PCP signaling in mesenchymal stem cells"**
- **作者**: Chen H. et al.
- **摘要**: 实验表明，阻断FZD8的抗体可通过调节Wnt/PCP(平面细胞极性)信号通路，促进间充质干细胞的成骨分化，为骨再生治疗提供新策略。
4. **"FZD8-specific antibody-drug conjugate suppresses tumor growth in FZD8-overexpressing ovarian cancer models"**
- **作者**: Wang Q. et al.
- **摘要**: 研究设计了一种FZD8抗体-药物偶联物(ADC)，在过表达FZD8的卵巢癌模型中显示出显著抗肿瘤活性，提示其作为靶向治疗的潜力。
这些研究展示了FZD8抗体在疾病机制研究、诊断及靶向治疗中的广泛应用。
FZD8 (Frizzled class receptor 8) is a member of the Frizzled family of G protein-coupled receptors, which play pivotal roles in the Wnt signaling pathway. This pathway is critical for embryonic development, tissue homeostasis, and stem cell regulation, with dysregulation linked to cancers and developmental disorders. FZD8 specifically binds Wnt ligands, initiating both canonical (β-catenin-dependent) and non-canonical signaling cascades. The extracellular cysteine-rich domain (CRD) of FZD8 mediates Wnt interaction, while its seven transmembrane helices facilitate downstream signal transduction.
FZD8 antibodies are immunological tools designed to detect, quantify, or modulate FZD8 activity. They are widely used in research to study Wnt signaling dynamics, tumorigenesis (e.g., colorectal, breast cancers), and tissue regeneration. Monoclonal antibodies targeting FZD8’s CRD have shown potential in blocking aberrant Wnt signaling in preclinical models, offering therapeutic avenues for cancers driven by Wnt/β-catenin hyperactivity. Conversely, agonist antibodies may enhance pathway activity for regenerative applications.
Commercial FZD8 antibodies are validated for techniques like Western blotting, immunofluorescence, and flow cytometry, often requiring specificity checks due to homology among Frizzled receptors. Recent studies also explore bispecific antibodies combining FZD8 targeting with other pathway inhibitors (e.g., LRP5/6 blockers) to improve therapeutic efficacy. Challenges remain in optimizing selectivity and minimizing off-target effects, but FZD8 antibodies continue to advance both mechanistic studies and drug development in Wnt-related diseases.
×
